Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease

Age at start of vaccine course

MenB vaccine brand

Dose requirements for people with a specified medical condition associated with increased risk of meningococcal disease

6 weeks to 5 months

Bexsero

4 doses (8 weeks between doses; 4th dose at 12 months of age or 8 weeks after 3rd dose, whichever is later)

6–11 months

Bexsero

3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later)

12 months to 9 years

Bexsero

2 doses (8 weeks between doses)

≥10 years

Bexsero

2 doses (8 weeks between doses)

Trumenba

3 doses (at intervals of 0, 1 and 6 months)